Nutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch

Rhea-AI Summary

Nutriband (NASDAQ:NTRB) selected a worldwide commercial brand name candidate for its lead product, an abuse‑deterrent fentanyl transdermal system, and will submit the proposed name and labeling to the FDA and other international regulators.

The company also filed for U.S. and international trademark protection, engaged Brand Institute for naming, and cites potential peak U.S. sales of $80M–$200M. The product uses Nutriband’s AVERSA abuse‑deterrent transdermal technology and is covered by patents in 46 countries.

Positive

• Brand name submission planned to FDA and international regulators
• Trademark filings initiated in the United States and internationally
• Peak U.S. sales estimate of $80M–$200M
• Patent coverage with patents issued in 46 countries

Negative

• Product remains in development; regulatory approval is pending
• Sales estimate range ($80M–$200M) is wide, indicating revenue uncertainty

Key Figures

Peak US sales (low): $80 million Peak US sales (high): $200 million Patent countries: 46 countries +5 more

8 metrics

Peak US sales (low) $80 million Potential peak annual US sales for abuse deterrent fentanyl patch

Peak US sales (high) $200 million Upper end of potential peak annual US sales range

Patent countries 46 countries AVERSA abuse-deterrent transdermal technology patent coverage

Global name approvals share 75% Brand Institute share of drug name approvals globally

FDA name approvals 2024 87% Brand Institute share of FDA-approved names in 2024

Quarterly revenue $346,058 Revenue for quarter ended Oct 31, 2025

Nine-month net loss $7.26M Net loss for nine months ended Oct 31, 2025

Preferred dividend value $21.81M Non-cash preferred stock dividend impacting 10-Q period

Market Reality Check

Price: $3.53 Vol: Volume 9,111 is below 20-...

low vol

$3.53 Last Close

Volume Volume 9,111 is below 20-day average 15,221 (relative volume 0.6) ahead of this news. low

Technical Shares at $3.86 are trading below the 200-day MA of $5.98, and about 66.95% under the 52-week high.

Peers on Argus

Peer moves appear mixed: among key biotech peers, some showed gains (e.g., CVM) ...

1 Up 1 Down

Peer moves appear mixed: among key biotech peers, some showed gains (e.g., CVM) while others declined (e.g., QNCX, STRO, XBIT), suggesting stock-specific dynamics rather than a broad sector move tied to this branding update.

Historical Context

5 past events · Latest: Mar 18 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 18	Regulatory approval	Positive	+0.5%	Costa Rica approval for kinesiology, AVERSA products, and patches.
Feb 17	Distribution deal	Positive	+4.0%	Exclusive AVERSA fentanyl and sports tape distribution in Costa Rica.
Jan 30	Shareholder meeting	Positive	+6.0%	Update on AVERSA Fentanyl progress, patents, and manufacturing scale-up.
Dec 31	Shareholder letter	Positive	-3.0%	CEO letter on 2025 milestones and 2026 outlook with AVERSA focus.
Dec 29	Asset sale	Positive	+16.0%	Sale of 90% of Pocono for $5M to fund AVERSA Fentanyl.

Pattern Detected

Recent company updates, especially around AVERSA Fentanyl and strategic deals, have more often coincided with positive price reactions than negative ones.

Recent Company History

Over the last few months, Nutriband has focused on advancing AVERSA Fentanyl and optimizing its portfolio. On Dec 29, 2025, it agreed to sell 90% of Pocono Pharmaceutical for $5.0M to fund AVERSA Fentanyl, a catalyst that saw a 16.04% gain. A 2025 shareholder letter on Dec 31, 2025 outlined milestones including a new USPTO patent and manufacturing scale-up but drew a -2.99% move. More recent 2026 updates on Costa Rica approvals and distribution agreements have aligned with modestly positive price reactions.

Market Pulse Summary

This announcement formalizes a key branding step for Nutriband’s AVERSA abuse‑deterrent fentanyl pat...

Analysis

This announcement formalizes a key branding step for Nutriband’s AVERSA abuse‑deterrent fentanyl patch, which is described as having potential peak US sales between $80M and $200M. It follows recent milestones including distribution deals and regulatory progress highlighted in late 2025 and early 2026. Investors may track future FDA and international reviews of the proposed name, additional AVERSA clinical or regulatory updates, and financial trends from filings such as the latest 10‑Q to gauge execution against these commercial ambitions.

Key Terms

transdermal, fentanyl, intellectual property, trademark registration, +4 more

8 terms

transdermal medical

"an abuse deterrent fentanyl transdermal system, and will submit to the FDA"

Transdermal describes a method of delivering a drug through the skin so the active ingredient is absorbed into the bloodstream, commonly via a patch, gel or cream. For investors, transdermal delivery affects a product’s convenience, steady dosing, patent and regulatory profile, manufacturing needs and market appeal—similar to a slow-release battery that makes a device easier to use and last longer, which can influence sales potential and risk.

fentanyl medical

"lead product, an abuse deterrent fentanyl transdermal system, and will submit"

Fentanyl is a very powerful synthetic opioid used medically to treat severe pain and, in illicit form, can be deadly at much smaller doses than other painkillers. Investors pay attention because its medical use, strict regulation, growing illegal market and related legal or public‑health actions can affect drugmakers, hospitals, emergency services and broader liability or demand for treatments—similar to how a single safety issue can reshape an entire industry.

intellectual property regulatory

"for trademark registration and to secure full intellectual property rights in"

Intellectual property are legal rights that protect creations of the mind—such as inventions, brand names, designs, software, or secret formulas—giving the owner control over who can use, copy or sell them. For investors, IP is like owning a blueprint or recipe: it can generate steady income through exclusive sales or licensing, boost a company’s competitive edge and valuation, and also create costs or risks if rights must be defended or challenged in court.

trademark registration regulatory

"name is being submitted to the United States Patent and Trademark Office for trademark registration"

Trademark registration is the official process of recording a brand name, logo, slogan, or other identifying mark with a government to gain legal protection against others using it. For investors, a registered trademark functions like a lock on a company’s identity—helping preserve customer recognition, enabling licensing or sale of brand rights, and reducing the risk of costly disputes, which can all affect future revenue and valuation.

averta abuse deterrent technology medical

"This product utilizes Nutriband’s AVERSA™ abuse deterrent transdermal technology"

AvertA abuse deterrent technology is a formulation approach built into certain prescription drugs—most often opioid pain medicines—that makes common misuse methods (crushing, dissolving, snorting or injecting) harder or less rewarding. For investors, such built‑in safeguards can affect regulatory approval, product labeling, legal exposure, payer acceptance and commercial value, because they change safety perception and market access much like adding a lock changes how a valuable item is handled and insured.

european medicines agency (ema) regulatory

"European Medicines Agency (EMA), Health Canada (HC), United States Adopted Name"

The European Medicines Agency (EMA) is a public organization responsible for evaluating and supervising medicines used in Europe to ensure they are safe and effective. For investors, the EMA's decisions can influence pharmaceutical companies' success, regulatory approvals, and the availability of new treatments, all of which can impact the value of related stocks and industry trends.

health canada (hc) regulatory

"European Medicines Agency (EMA), Health Canada (HC), United States Adopted Name"

Health Canada (HC) is the Canadian federal department that reviews and approves drugs, medical devices, vaccines and related health products, sets safety rules, and oversees clinical trial and product labeling standards. Investors watch HC decisions because its approvals or safety actions determine whether a medical product can reach Canadian patients, affecting a company’s sales, timelines and perceived risk — similar to a building inspector whose sign-off is needed before a project can open to the public.

world health organization (who) regulatory

"United States Adopted Name Council (USAN), and World Health Organization (WHO)"

The World Health Organization (WHO) is the United Nations agency that coordinates international public health guidance, disease surveillance, and response efforts across countries. Investors watch WHO announcements because its guidance and alerts — similar to a global health traffic controller directing where resources and restrictions should move — can change government policies, travel and trade flows, pharmaceutical demand, and market sentiment, all of which can affect company revenues and stock prices.

AI-generated analysis. Not financial advice.

Nutriband has selected the commercial worldwide brand name for its lead product, an abuse deterrent fentanyl transdermal system, and will submit to the FDA for approval per FDA Guidance.

Nutriband partnered with Brand Institute, Inc, the global leader in pharmaceutical and healthcare-related brand name and identity development.

ORLANDO, Fla., March 30, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has selected the commercial worldwide brand name candidate for its lead product, an abuse deterrent fentanyl transdermal system. The proposed brand name and product labeling will be submitted to the FDA and other international regulatory agencies for review and approval. In addition, the selected name is being submitted to the United States Patent and Trademark Office for trademark registration and to secure full intellectual property rights in the United States and internationally.

The company engaged Brand Institute, Inc, the global leader in pharmaceutical and healthcare-related brand name and identity development services to develop the worldwide commercial brand name and visual identity for the product. This product utilizes Nutriband’s AVERSA™ abuse deterrent transdermal technology and has the potential to be the world’s first abuse-deterrent patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl.

Nutriband’s abuse deterrent fentanyl transdermal system has the potential to reach peak annual US sales of $80 million to $200 million.¹ While initially concentrating on the US market, the unmet medical need for adequate pain management is a global problem, and the product is in development for all major medical markets worldwide.

Developing a proprietary brand name for a prescription drug product is a critical element in drug product development because the end users (doctors, pharmacists, patients) must be able to easily distinguish a proprietary name from other drug names that are phonetically similar (sound-alike names) or similar in their spelling or appearance (look-alike names). In addition, if the drug name is otherwise confusing or misleading, the patient might receive the wrong product and the subsequent medication error could lead to significant harm to the patient.

Brand Institute has been leading the market for over 20 years with a 75% share of drug name approvals globally, including 87% of FDA approved names in 2024. In addition, Brand Institute has been responsible for many of the opioid chronic pain product brand names and specifically a majority of the abuse deterrent opioid product brand names approved by FDA for sale in the United States.

Drug Safety Institute (DSI), a wholly owned regulatory subsidiary of Brand Institute, will provide regulatory services, solutions and support on the project. DSI is led by former officials from US Food & Drug Administration (FDA), European Medicines Agency (EMA), Health Canada (HC), United States Adopted Name Council (USAN), and World Health Organization (WHO) who co-authored the naming guidance documents while with their former respective agencies.

Nutriband’s AVERSA™ abuse-deterrent technology is utilized to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential including opioids and stimulants. The AVERSA™ abuse deterrent technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

¹ Health Advances Aversa Fentanyl market analysis report 2022

About AVERSA™ Abuse-Deterrent Transdermal Technology

Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

About Nutriband, Inc.

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.

About Brand Institute, Inc., and wholly owned regulatory subsidiary, Drug Safety Institute

Brand Institute is the global leader in pharmaceutical and healthcare-related name development, with a portfolio of over 5,000 marketed healthcare brand names and 1,800 USAN/INN nonproprietary names for nearly 1,600 clients. The company partners on over 75% of pharmaceutical brand and nonproprietary name approvals globally every year with healthcare manufacturers. Drug Safety Institute is composed of former naming regulatory officials from global government health agencies, including Food and Drug Administration (FDA), European Medicines Agency (EMA), Health Canada (HC), American Medical Association (AMA), and the World Health Organization (WHO). These regulatory experts co-authored the name review guidelines while with their former respective agencies, with many responsible for ultimately approving (or rejecting) brand name applications to ensure safety and prevent medication errors. To learn more about Brand Institute's capabilities and experience, please visit www.brandinstitute.com and contact your local Brand Institute representative.

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words "believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Forms 10-K’s and Forms 10-Q’s, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

Nutriband is a registered trademark of Nutriband, Inc. AVERSA is a trademark of Nutriband, Inc.

Brand Institute and Drug Safety Institute are registered trademarks of Brand Institute, Inc.

Contact Information:

Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com

SOURCE: Nutriband Inc.

FAQ

What action did Nutriband (NTRB) take on March 30, 2026 regarding its fentanyl patch brand name?

Nutriband selected a worldwide commercial brand name candidate and will submit it for regulator review. According to the company, the proposed name and labeling will be submitted to the FDA and other international agencies for approval and trademark registration.

How large is Nutriband’s (NTRB) projected peak U.S. market for the AVERSA fentanyl patch?

Nutriband projects peak annual U.S. sales between $80 million and $200 million. According to the company, this figure comes from a market analysis and represents potential peak sales, not regulatory approval or guaranteed revenue.

Has Nutriband (NTRB) protected the AVERSA technology with patents internationally?

Yes. Nutriband reports patents issued in 46 countries for its AVERSA technology. According to the company, the intellectual property portfolio includes issued patents across the United States, Europe, Japan, China, and other major markets.

Will Nutriband (NTRB) apply for trademark protection for the new fentanyl patch name?

Yes. The company is submitting the selected name to the U.S. Patent and Trademark Office and international trademark authorities. According to the company, filings aim to secure full intellectual property rights domestically and abroad.

What regulatory steps will Nutriband (NTRB) follow for its abuse‑deterrent fentanyl patch?

Nutriband will submit proposed product name and labeling to FDA and other regulators per guidance. According to the company, Drug Safety Institute will support regulatory services and naming review for approval processes.

How might the new brand name affect Nutriband’s (NTRB) product safety and market adoption?

A distinct proprietary name aims to reduce medication errors and confusion with other drugs. According to the company, clear naming helps doctors, pharmacists, and patients distinguish the product and supports safe prescribing and dispensing.